BDH Pharma, LLC, is a pharmaceutical startup developing medication for the treatment of pain and opioid use disorders. Our mission is to improve the health of patients suffering from chronic pain and opioid use disorders through safer and more effective alternatives to current analgesics and medical marijuana. As 50 million US adults seek analgesia for chronic pain, opioid abuse/overdose rates have skyrocketed. Others have turned to medical marijuana though it is illegal at the federal level, is not FDA-approved for pain or opioid use disorders, and is of variable quality. Safer, more effective medication for chronic pain is urgently needed. Our lead candidate BDH-001, a novel fixed-dose combination of an opioid and a cannabinoid, exhibits synergistic and opioid-sparing effects, resulting in lower risk of respiratory depression, physical tolerance/dependence, and addiction, underscoring the advantages of our combination therapeutic compared to available analgesics/medical marijuana.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):